A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Clinical trial NCT04616326 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04616326
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-25
- Primary completion
- 2025-12-10
- Enrollment
- 312
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.